Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma

G. Holló, Andreas Katsanos

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: The preservative-free (PF) fixed combination (FC) of tafluprost 0.0015%/timolol 0.5% is the newest member of the prostaglandin analogue/timolol FC class.Areas covered: In this review, we summarize data on safety and tolerability of this FC.Expert opinion: The intraocular pressure-lowering effect of the tafluprost/timolol FC is approximately 30-35%, which is similar to that of the other members of the class. However, in contrast to most similar eye drops the tafluprost/timolol FC is manufactured in a PF, unit-dose pipette formulation. The PF nature eliminates preservative-related ocular surface changes, and improves tolerability. In clinical studies, the tafluprost/timolol FC was well tolerated. The side effects represented the typical side effects of the topical prostaglandin analogue class. The most common side effect, conjunctival hyperemia was mild, and occurred in only 6.4-8% of patients during 6 months of treatment. The figures for ocular irritation were also low (7.0-12.7%). The other side effects occurred only in very few patients. The frequency and severity of conjunctival hyperemia was lower than those published for most prostaglandin/timolol FCs. Thus, the main clinical advantage of this PF FC is improved tolerability, which may support treatment adherence of glaucoma patients.

Original languageEnglish
Pages (from-to)609-617
Number of pages9
JournalExpert Opinion on Drug Safety
Volume14
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Timolol
Glaucoma
Safety
Synthetic Prostaglandins
Hyperemia
Therapeutics
Ophthalmic Solutions
Expert Testimony
Patient Compliance
Intraocular Pressure
Prostaglandins
tafluprost

Keywords

  • Conjunctival hyperemia
  • Glaucoma
  • Prostaglandin analogue
  • Side effect
  • Tafluprost/timolol fixed combination
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. / Holló, G.; Katsanos, Andreas.

In: Expert Opinion on Drug Safety, Vol. 14, No. 4, 01.04.2015, p. 609-617.

Research output: Contribution to journalArticle

@article{512ee94838194c53858a9d1ad758b7cf,
title = "Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma",
abstract = "Introduction: The preservative-free (PF) fixed combination (FC) of tafluprost 0.0015{\%}/timolol 0.5{\%} is the newest member of the prostaglandin analogue/timolol FC class.Areas covered: In this review, we summarize data on safety and tolerability of this FC.Expert opinion: The intraocular pressure-lowering effect of the tafluprost/timolol FC is approximately 30-35{\%}, which is similar to that of the other members of the class. However, in contrast to most similar eye drops the tafluprost/timolol FC is manufactured in a PF, unit-dose pipette formulation. The PF nature eliminates preservative-related ocular surface changes, and improves tolerability. In clinical studies, the tafluprost/timolol FC was well tolerated. The side effects represented the typical side effects of the topical prostaglandin analogue class. The most common side effect, conjunctival hyperemia was mild, and occurred in only 6.4-8{\%} of patients during 6 months of treatment. The figures for ocular irritation were also low (7.0-12.7{\%}). The other side effects occurred only in very few patients. The frequency and severity of conjunctival hyperemia was lower than those published for most prostaglandin/timolol FCs. Thus, the main clinical advantage of this PF FC is improved tolerability, which may support treatment adherence of glaucoma patients.",
keywords = "Conjunctival hyperemia, Glaucoma, Prostaglandin analogue, Side effect, Tafluprost/timolol fixed combination, Tolerability",
author = "G. Holl{\'o} and Andreas Katsanos",
year = "2015",
month = "4",
day = "1",
doi = "10.1517/14740338.2015.1010507",
language = "English",
volume = "14",
pages = "609--617",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma

AU - Holló, G.

AU - Katsanos, Andreas

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: The preservative-free (PF) fixed combination (FC) of tafluprost 0.0015%/timolol 0.5% is the newest member of the prostaglandin analogue/timolol FC class.Areas covered: In this review, we summarize data on safety and tolerability of this FC.Expert opinion: The intraocular pressure-lowering effect of the tafluprost/timolol FC is approximately 30-35%, which is similar to that of the other members of the class. However, in contrast to most similar eye drops the tafluprost/timolol FC is manufactured in a PF, unit-dose pipette formulation. The PF nature eliminates preservative-related ocular surface changes, and improves tolerability. In clinical studies, the tafluprost/timolol FC was well tolerated. The side effects represented the typical side effects of the topical prostaglandin analogue class. The most common side effect, conjunctival hyperemia was mild, and occurred in only 6.4-8% of patients during 6 months of treatment. The figures for ocular irritation were also low (7.0-12.7%). The other side effects occurred only in very few patients. The frequency and severity of conjunctival hyperemia was lower than those published for most prostaglandin/timolol FCs. Thus, the main clinical advantage of this PF FC is improved tolerability, which may support treatment adherence of glaucoma patients.

AB - Introduction: The preservative-free (PF) fixed combination (FC) of tafluprost 0.0015%/timolol 0.5% is the newest member of the prostaglandin analogue/timolol FC class.Areas covered: In this review, we summarize data on safety and tolerability of this FC.Expert opinion: The intraocular pressure-lowering effect of the tafluprost/timolol FC is approximately 30-35%, which is similar to that of the other members of the class. However, in contrast to most similar eye drops the tafluprost/timolol FC is manufactured in a PF, unit-dose pipette formulation. The PF nature eliminates preservative-related ocular surface changes, and improves tolerability. In clinical studies, the tafluprost/timolol FC was well tolerated. The side effects represented the typical side effects of the topical prostaglandin analogue class. The most common side effect, conjunctival hyperemia was mild, and occurred in only 6.4-8% of patients during 6 months of treatment. The figures for ocular irritation were also low (7.0-12.7%). The other side effects occurred only in very few patients. The frequency and severity of conjunctival hyperemia was lower than those published for most prostaglandin/timolol FCs. Thus, the main clinical advantage of this PF FC is improved tolerability, which may support treatment adherence of glaucoma patients.

KW - Conjunctival hyperemia

KW - Glaucoma

KW - Prostaglandin analogue

KW - Side effect

KW - Tafluprost/timolol fixed combination

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84924955002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924955002&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1010507

DO - 10.1517/14740338.2015.1010507

M3 - Article

C2 - 25640746

AN - SCOPUS:84924955002

VL - 14

SP - 609

EP - 617

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -